Vittoria Biotherapeutics, Inc.
Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies to address unmet clinical needs.
Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies to address unmet clinical needs.
Vittoria Biotherapeutics, Inc. is a biotechnology startup founded in 2021, based in the United States. The company is dedicated to unlocking the potential of cell therapies to address unmet clinical needs. Their focus lies in strengthening efficacy, improving safety, and broadening therapeutic applicability for patients with difficult-to-treat diseases.
Notably, Vittoria Biotherapeutics recently secured a substantial $15.00M Venture Round investment on 14 November 2023. The investors behind this funding round include BioAdvance, Agent Capital, Tellus BioVentures, Valley Forge Investment Corporation, NYBC Ventures, University of Pennsylvania, and The Leukemia & Lymphoma Society’s Therapy Acceleration Program.
This latest injection of capital reflects a strong show of confidence in Vittoria Biotherapeutics' mission and the potential of their approach to cell therapies. The company's commitment to privacy is also notable, as they emphasize their discretion in handling sensitive personal information and provide guidance on avoiding potential fraudulent schemes related to career opportunities. As the biotechnology industry continues to expand, Vittoria Biotherapeutics seems poised to make significant strides in leveraging cell therapies to enhance patient care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $15.00M | 7 |
|
14 Nov 2023 |
| Seed Round | $10.00M | 3 |
|
07 Jun 2022 |
No recent news or press coverage available for Vittoria Biotherapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
